Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 9Dermatologic 4Thoracic 3Gynecologic 3Gastrointestinal 3Breast 2Sarcoma 1NET 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 12Colorectal Neoplasms 8Lung Neoplasms 7Ovarian Neoplasms 6Neoplasms 5Mesothelioma, Malignant 5Carcinoma, Renal Cell 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Merkel Cell 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

pembrolizumab 34Cisplatin 12Nivolumab 10atezolizumab 9Docetaxel 9Carboplatin 9Paclitaxel 8Cetuximab 8Gemcitabine 7Blood Specimen Collection 7Radiotherapy 6Fluorouracil 6Drug Therapy 6cemiplimab 5Pemetrexed 5Immune Checkpoint Inhibitors 5fludarabine 4Standard of Care 4Cyclophosphamide 4spartalizumab 3epacadostat 3Surveys and Questionnaires 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Interleukin-2 3Filgrastim 3Bupropion 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Interleukin-2 × Thoracic × Clear all
NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
15 enrolled
DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡